Skip to content

FURAZOLIDONE VS CIPROFLOXACIN IN THE TREATMENT OF MILD OR MODERATE DYSENTERY IN CHILDREN UNDER 5 YEARS OLD: A SINGLE BLIND, RANDOMIZED CLINICAL TRIAL OF NON-INFERIORITY.

FURAZOLIDONE VS CIPROFLOXACIN IN THE TREATMENT OF MILD OR MODERATE DYSENTERY IN CHILDREN UNDER 5 YEARS OLD: A SINGLE BLIND, RANDOMIZED CLINICAL TRIAL OF NON-INFERIORITY.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-097-11
Enrollment
378
Registered
2011-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

WE WILL WORK WITH 378 CHILDREN UNDER 5 YEARS OLD WITH DYSENTERY ATTENDING AT 4 LIMA HOSPITALS: NATIONAL HOSPITAL CAYETANO HEREDIA, PEDIATRIC EMERGENCY HOSPITAL, HOSPITAL SAN BARTOLOME AND THE NATIONAL

Sponsors

UNIVERSIDAD PERUANA CAYETANO HEREDIA, Instituto Nacional de Salud del Niño,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 60 Years

Inclusion criteria

Inclusion criteria: • EVERY PATIENT TO BE INCLUDED IN THIS STUDY IS OVER 12 MONTHS AND UNDER 5 YEARS (60 MONTHS) OF AGE, WITH THIS PICTURE OF MILD DYSENTERY (AQUEOUS DIARRHEA WITH FEVER AND PRESENCE OF RED CELLS AND PLATELETS> 50 FOR FIELD) OR MODERATE DYSENTERY 72hrs OR LESS DURATION AND GO TO BE ATTENDED IN HOSPITALS SELECTED FOR THE STUDY.

Exclusion criteria

Exclusion criteria: • CHILDREN WITH A PREVIOUS DIAGNOSIS OF CONDITIONS TO BE CONSIDERED CONTRAINDICATIONS FOR TREATMENT WITH FURAZOLIDONE, SUCH AS LACK OF GLUCOSE 6 PHOSPHATE DEHYDROGENASE, HEMOLYTIC ANEMIA RELATED TO G6PD AND KINASE PYRUVATE DEFICIENCY. • CHILDREN COMORBIDITIES BACKGROUND AFFECTING THE IMMUNE STATE AND THEN THE CLINIC (INFECTION WITH HIV, AIDS; CHRONIC DISEASES: LIVER, KIDNEY, HEART, KIDNEY FAILURE, SEVERE MALNUTRITION). • CHILDREN KNOW THAT HAS RECEIVED DIPHENOXYLATE HYDROCHLORIDE THERAPY WITH ATROPINE OR LOPERAMIDE, BECAUSE OF THE RISK OF EXTENDING DISEASE. • CHILDREN WITH PRIOR ALLERGIC OR HYPERSENSITIVITY TO FLUOROQUINOLONES OR OTHER DERIVATIVES OF QUINOLONES. • CHILDREN WITH TENDINITIS BACKGROUND OR BREACH OF TENDON, CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING CEREBRAL ATHEROSCLEROSIS, EPILEPSY, OR OTHER FACTORS THAT PREDISPOSE TO SEIZURE. • CHILDREN THAT HAVE RECEIVED ANY DOSE OF ANTIBIOTICS IN THE LAST 72 HOURS DURING THE CURRENT CLINICAL CONDITION. • PATIENTS WHOSE PARENTS refuse to PARTICIPATE IN THE STUDY OR NOT SIGN THE INFORMED CONSENT.

Countries

France

Contacts

Public ContactTheresa Jean Ochoa

UNIVERSIDAD PERUANA CAYETANO HEREDIA

Theresa.J.Ochoa@uth.tmc.edu996505308

Outcome results

None listed

Source: REPEC (via WHO ICTRP)